Mechanistically, these EMT-driving transcription factors are activated in response to a variety of stimuli and subsequently lead to cell reprogramming [43] through mediating signaling crosstalk among different oncogenic pathways such as TGFβ [44, 45] and Notch [46], and significantly contribute to drug resistance in clinical cancer therapy [47]. The gene discussed is TGFB1; the disease is cancer.